- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 2 - Histology, Targeted Therapy and Surgery
Dr Langer suggests that historically, there's been a monolithic approach to treating NSCLC.
Dr Langer suggests that historically, there’s been a “monolithic approach” to treating NSCLC. “The histologic distinctions have really come to the forefront now in advanced disease, whereas perhaps 8 to 10 years ago it didn’t really make much of a difference,” he says, “so we are holding our pathologists’ ‘feet to the fire.’”
The panel also discusses targeted therapy and surgery in treatment of NSCLC.
Dr Sugarbaker says surgery is dynamic, noting there are a number of techniques to resect or remove the tumor with technology’s help. “These have significantly reduced the morbidity or the stress and pain for the patient.”
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
